New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorUniversity Hospital, Bordeaux
About this trial
Gestational diabetes mellitus (GDM) increases the risk of macrosomia and other adverse pregnancy outcomes. Screening strategies are debated: universal vs. selective, and macrosomia may begin before the time of screening, suggesting that glycation markers may have an interest. The objective of this trail is to compare novel markers: skin autofluorescence and glycated albumin, to HbA1c (reference) as predictors of GDM, macrosomia and other adverse outcomes, in pregnant women.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Singleton pregnancy (or twin pregnancy reduced spontaneously or medically before 14 weeks of amenorrhea)
Gestational age at inclusion <28 weeks of amenorrhea
Participant affiliated with or beneficiary of a social security scheme
Disqualifiers
Gestational age at inclusion ≥ 28 weeks of amenorrhea
Multiple pregnancy
Known diabetes prior to pregnancy
History of bariatric surgery
Trial design
Treatments tested in this trial
- Pregnant women
Treatment groups
800 Participants
are divided into 1 treatment groupLocations
1Hopital Pellegrin33000, Bordeaux France
Sponsors and collaborators
University Hospital, Bordeaux
Lead sponsor
Société Francophone du Diabète
Collaborator
Source ClinicalTrials.gov